Premium
Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus
Author(s) -
Imamura Ryoichi,
Ichimaru Naotsugu,
Moriyama Toshiki,
Shi Yi,
Namba Yukiomi,
omura Norio,
Matsumiya Kiyomi,
Toki Kiyohide,
Takahara Shiro,
Okuyama Akihiko
Publication year - 2005
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2005.00341.x
Subject(s) - simvastatin , medicine , transplantation , hyperlipidemia , hypertriglyceridemia , endocrinology , tacrolimus , cholesterol , gastroenterology , triglyceride , kidney transplantation , diabetes mellitus
Background: Hyperlipidemia is frequently developed following renal transplantation and results in worsening of the patient's prognosis. Methods: In this study, 14 patients who had hypercholesterolemia [total cholesterol (TC) >200 mg/dL] and hypertriglyceridemia [triglyceride (TG) >150 mg/dL] 1 month after renal transplantation (post‐transplantation), seven patients each under the treatment with immunosuppressant, either cyclosporine or tacrolimus started simvastatin treatment of 5–10 mg/d and continued the treatment for 4 yr. The effect of simvastatin treatment was assessed by comparison in serum lipid levels (TC, TG, cholesterol in lipoprotein fractions, and apolipoproteins) and the lipid metabolism related enzyme activities for post‐transplantation, after 6‐month and 4‐yr simvastatin treatment. Results: Simvastatin treatment of 4 yr significantly decreased the elevated levels of serum TC from 234.5 ± 30.8 to 186.3 ± 20.5 mg/dL (p < 0.001), low density lipoprotein cholesterol (LDL‐C) from116.7 ± 22.5 to 82.7 ± 16.6 mg/dL (p < 0.05) and TG from 200.3 ± 109.2 to 97.0 ± 45.2 mg/dL (p < 0.001). In addition, there were significant decreases in elevated serum very‐low‐density lipoprotein cholesterol (VLDL‐C) from 47.8 ± 18.4 to 28.6 ± 9.5 mg/dL (p < 0.001) and LDL2 cholesterol (LDL2‐C) from 20.8 ± 8.2 to 5.7 ± 1.8 mg/dL (p < 0.001). Conclusion: The results indicate that 4‐yr treatment of simvastatin improves profiles of the atherogenic lipids in renal transplant patients with immunosuppressant caused hypercholesterolemia and hypertriglyceridemia treated either cyclosporine or tacrolimus in similar manner.